Exenatide bid observational study (ExOS): Baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting

Current Medical Research and Opinion

Volumn 27, Issue 3, 2011, Pages 531-540

  Bergenstal, Richard M ^a   Garrison Jr , Louis P ^b   Wintle, Matthew ^c   Blickensderfer, Amy ^c   Wade, Rolin ^d   Hou, Likun ^d   Miller, Lesley Ann ^e   Scism Bacon, Jamie ^e   Zagar, Anthony ^e   Misurski, Derek ^e   Herman, William H ^f  

^a INTERNATIONAL DIABETES CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c AMYLIN PHARMACEUTICALS INC   (United States)

^d HEALTHCORE INC   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Diabetes; Exenatide; HbA1c; Obesity; Observational; Weight

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; EZETIMIBE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; SULFONYLUREA; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASIAN; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE SEVERITY; DYSLIPIDEMIA; EATING HABIT; EDUCATIONAL STATUS; ETHNICITY; EUROPEAN AMERICAN; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HISPANIC; HUMAN; HYPERTENSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; PACIFIC ISLANDS; PHYSICAL ACTIVITY; PROSPECTIVE STUDY; QUALITY OF LIFE; SELF ESTEEM; SEXUAL BEHAVIOR; SMOKING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OBSERVATION; PEPTIDES; POPULATION; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; QUESTIONNAIRES; SOCIAL CLASS; TREATMENT OUTCOME; VENOMS;

EID: 79951668719     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.545814     Document Type: Article

References (37)

1. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exen-din-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117:77-88 (Pubitemid 38045329)
2. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001;281:E155-61
3. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfo-nylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26:2370-7 (Pubitemid 36993328)
4. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-9 (Pubitemid 36877476)
5. Nielsen LL, Baron AD. Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Investig Drugs 2003;4:401-5 (Pubitemid 36686678)
6. Parkes DG, Pittner R, Jodka C, et al. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001;50:583-9 (Pubitemid 32433049)
7. Young AA, Gedulin BR, Bhavsar S, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999;48:1026-34 (Pubitemid 29226349)
8. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35 (Pubitemid 39441462)
9. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100 (Pubitemid 40616618)
10. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91 (Pubitemid 40616617)
11. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-86 (Pubitemid 351160260)
12. Brixner DI, McAdam-Marx C, Ye X, et al. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metab 2009; 11:1122-30
13. Brixner DI, Mc-Adam-Marx C, Ye X, et al. Real-world six month outcomes of patients intiating exenatide in a primary care electronic medical record database [ISPOR abstract DB1]. Value Health 2008;11(Suppl):A17
14. Brixner DI, Mc-Adam-Marx C, Ye X, et al. 18 month A1C and weight outcomes of exenatide therapy in patients with type 2 diabetes in a real-world study [ISPOR abstract PDB6]. Value Health 2009;12(Suppl):A97
15. Fabunmi R, Mc-Adam-Marx C, Ye X, et al. Blood pressure outcomes after 6 months of exenatide treatment in patients with type 2 diabetes in a real world study [ADA abstract 470-P]. Diabetes 2009;58(Suppl 1)
16. Mc-Adam-Marx C, Brixner DI, Ye X, et al. A1C and weight outcomes following 6 months of analog basil insulin in insulin-na?̈ve patients with type 2 diabetes in an ambulatory care setting [ISPOR abstract PDB2]. Value Health 2009; 12(Suppl):A97
17. Wade R, Quimbo R, Fabunmi R, et al. Utilization patterns and hypoglycemia in patients with type 2 diabetes on concomitant exenatide and long-acting insulin therapy [ISPOR abstract PDB15]. Value Health 2009;12(Suppl):A99
18. Fabunmi R, Nielsen LL, Quimbo R, et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 2009;25:777-86
19. American Diabetes Association. Standards of medical care in diabetes- 2007. Diabetes Care 2007;30:S4-41
20. Engel SG, Crosby RD, Kolotkin RL, et al. Impact of weight loss and regain on quality of life: mirror image or differential effect? Obes Res 2003; 11:1207-13 (Pubitemid 41127374)
21. Kolotkin RL, Crosby RD. Psychometric evaluation of the impact of weight on quality of life-lite questionnaire (IWQOL-lite) in a community sample. Qual Life Res 2002;11:157-71 (Pubitemid 34438162)
22. Kolotkin RL, Crosby RD, Kosloski KD, et al. Development of a brief measure to assess quality of life in obesity. Obes Res 2001;9:102-11 (Pubitemid 33603836)
23. Kolotkin RL, Crosby RD, Pendleton R, et al. Health-related quality of life in patients seeking gastric bypass surgery vs non-treatment-seeking controls. Obes Surg 2003;13:371-7 (Pubitemid 36718455)
24. Kolotkin RL, Crosby RD, Williams GR. Health-related quality of life varies among obese subgroups. Obes Res 2002;10:748-56 (Pubitemid 135687515)
25. Kolotkin RL, Crosby RD, Williams GR, et al. The relationship between health-related quality of life and weight loss. Obes Res 2001;9:564-71 (Pubitemid 33610177)
26. White MA, Whisenhunt BL, Williamson DA, et al. Development and validation of the food-craving inventory. Obes Res 2002;10:107-14 (Pubitemid 135687498)
27. Kroenke K, Spitzer RL. The PHQ-9: a new depression and diagnostic severity measure. Psychiatr Ann 2002;32:509-21
28. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-13 (Pubitemid 32823891)
29. Lowe B, Unutzer J, Callahan CM, et al. Monitoring depression treatment outcomes with the patient health questionnaire-9. Med Care 2004; 42:1194-201 (Pubitemid 39627296)
30. Pinto-Meza A, Serrano-Blanco A, Penarrubia MT, et al. Assessing depression in primary care with the PHQ-9: can it be carried out over the telephone? J Gen Intern Med 2005;20:738-42 (Pubitemid 41141006)
31. Rost K, Smith J. Retooling multiple levels to improve primary care depression treatment. J Gen Intern Med 2001;16:644-5 (Pubitemid 32823898)
32. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999;282:1737-44 (Pubitemid 29533604)
33. Williams Jr JW, Noel PH, Cordes JA, et al. Is this patient clinically depressed? JAMA 2002;287:1160-70 (Pubitemid 34252086)
34. American Diabetes Association. Standards of medical care in diabetes- 2009. Diabetes Care 2009;32:S13-61
35. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20 (Pubitemid 38196703)
36. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;30:1448-60
37. Gregg EW, Gu Q, Cheng YJ, et al. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med 2007;147:149-55 (Pubitemid 351664594)